A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients Journal Article
| Authors: | Lee, E. Q.; Kaley, T. J.; Duda, D. G.; Schiff, D.; Lassman, A. B.; Wong, E. T.; Mikkelsen, T.; Purow, B. W.; Muzikansky, A.; Ancukiewicz, M.; Huse, J. T.; Ramkissoon, S.; Drappatz, J.; Norden, A. D.; Beroukhim, R.; Weiss, S. E.; Alexander, B. M.; McCluskey, C. S.; Gerard, M.; Smith, K. H.; Jain, R. K.; Batchelor, T. T.; Ligon, K. L.; Wen, P. Y. |
| Article Title: | A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients |
| Abstract: | Purpose: Vandetanib, a tyrosine kinase inhibitor of KDR (VEGFR2), EGFR, and RET, may enhance sensitivity to chemotherapy and radiation. We conducted a randomized, noncomparative, phase II study of radiation (RT) and temozolomide with or without vandetanib in patients with newly diagnosed glioblastoma (GBM). Experimental Design: We planned to randomize a total of 114 newly diagnosed GBM patients in a ratio of 2: 1 to standard RT and temozolomide with (76 patients) or without (38 patients) vandetanib 100 mg daily. Patients with age ≥ 18 years, Karnofsky performance status (KPS) ≥ 60, and not on enzyme-inducing antiepileptics were eligible. Primary end-point was median overall survival (OS) from the date of randomization. Secondary endpoints included median progression-free survival (PFS), 12-month PFS, and safety. Correlative studies included pharmacokinetics as well as tissue and serum biomarker analysis. Results: The study was terminated early for futility based on the results of an interim analysis. We enrolled 106 patients (36 in the RT/temozolomide arm and 70 in the vandetanib/RT/temozolomide arm). Median OS was 15.9 months [95% confidence interval (CI), 11.0-22.5 months] in the RT/temozolomide arm and 16.6 months (95% CI, 14.9-20.1 months) in the vandetanib/RT/temozolomide (log-rank P = 0.75). Conclusions: The addition of vandetanib at a dose of 100 mg daily to standard chemoradiation in patients with newly diagnosed GBM or gliosarcoma was associated with potential pharmacodynamic biomarker changes and was reasonably well tolerated. However, the regimen did not significantly prolong OS compared with the parallel control arm, leading to early termination of the study. © 2015 American Association for Cancer Research. |
| Keywords: | adult; controlled study; aged; major clinical study; overall survival; drug tolerability; fatigue; neutropenia; diarrhea; drug safety; hypertension; hypophosphatemia; adjuvant therapy; gadolinium; temozolomide; progression free survival; infection; multiple cycle treatment; phase 2 clinical trial; anemia; leukopenia; randomized controlled trial; thrombocytopenia; alanine aminotransferase blood level; aspartate aminotransferase blood level; dizziness; dyspnea; hyperglycemia; lymphocytopenia; pruritus; rash; hypoxia; alanine aminotransferase; aspartate aminotransferase; hyponatremia; karnofsky performance status; add on therapy; multicenter study; thrombosis; glioblastoma; acne; vandetanib; open study; hyperbilirubinemia; colon perforation; weakness; headache; drug blood level; embolism; drug half life; brain ischemia; gliosarcoma; cholecystitis; chemoradiotherapy; desquamation; thrombus; erythema multiforme; colon fistula; human; male; female; priority journal; article |
| Journal Title: | Clinical Cancer Research |
| Volume: | 21 |
| Issue: | 16 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2015-08-15 |
| Start Page: | 3610 |
| End Page: | 3618 |
| Language: | English |
| DOI: | 10.1158/1078-0432.ccr-14-3220 |
| PROVIDER: | scopus |
| PUBMED: | 25910950 |
| PMCID: | PMC4790106 |
| DOI/URL: | |
| Notes: | Export Date: 2 November 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work